5.8012

4.98% 0.2812

Precigen Inc (PGEN)

Overview News Price History Option Chain Financials Discussions Forecast

Precigen Inc stock is traded at $5.8012, with a volume of 1.75M. It is up +4.98% in the last 24 hours and up +36.67% over the past month. Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.

Previous Close:

$5.52

Open:

$5.5

24h Volume:

1.75M

Relative Volume:

0.36

Market Cap:

$2.07B

Revenue:

$9.68M

Net Income/Loss:

$-250.64M

P/E Ratio:

-4.1443

EPS:

-1.3998

Net Cash Flow:

$-89.83M

1W Performance:

+20.23%

1M Performance:

+36.67%

6M Performance:

+39.30%

1Y Performance:

+305.24%

1-Day Range:

$5.482

$5.95

1-Week Range:

$4.89

$5.95

52-Week Range:

$1.39

$5.95

Precigen Inc Stock (PGEN) Company Profile

Name

Precigen Inc

Sector

Healthcare (1103)

Industry

Biotechnology (619)

Phone

301-556-9900

Address

20374 SENECA MEADOWS PARKWAY, GERMANTOWN, MD

Employee

Twitter

@precigen

Next Earnings Date

2026-08-11

Latest SEC Filings

PGEN's Discussions on Twitter

Compare PGEN vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PGEN Precigen Inc	5.80	1.93B	9.68M	-250.64M	-89.83M	-1.3998
VRTX Vertex Pharmaceuticals Inc	499.03	120.61B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	635.71	65.36B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	898.48	53.02B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	299.01	39.26B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	179.84	36.09B	742.00K	-1.37B	-1.07B	-7.0731

Precigen Inc Stock (PGEN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Aug-15-25	Upgrade	JP Morgan	Underweight → Neutral
Mar-22-24	Downgrade	JP Morgan	Neutral → Underweight
May-23-23	Initiated	JP Morgan	Neutral
Nov-18-22	Initiated	Cantor Fitzgerald	Overweight
Feb-25-21	Initiated	Stifel	Buy
Feb-22-21	Initiated	Wells Fargo	Overweight
Feb-18-21	Initiated	B. Riley Securities	Buy
May-08-20	Initiated	H.C. Wainwright	Buy

View All

Precigen Inc Stock (PGEN) Latest News

Jun 25, 2026

Price to sales forward of Precigen, Inc. – NASDAQ:PGEN - TradingView

Jun 25, 2026

Jun 24, 2026

Precigen (PGEN) investors back 7M-share incentive pool and all board picks - Stock Titan

Jun 24, 2026

Clearfield And 2 Insider Picks For Strong Growth - simplywall.st

Jun 24, 2026

Precigen (PGEN) Is Up 12.1% After Orphan Exclusivity Win for PAPZIMEOS TherapyWhat's Changed - Sahm

Jun 24, 2026

Jun 23, 2026

Precigen stock hits 52-week high at 5.47 USD By Investing.com - Investing.com Australia

Jun 23, 2026

Precigen stock hits 52-week high at 5.47 USD - Investing.com

Jun 23, 2026